Cara Therapeutics Receivables 2012-2024 | CARA

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Cara Therapeutics receivables from 2012 to 2024. Receivables can be defined as the total amount of collectibles for a company

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Cara Therapeutics receivables from 2012 to 2024. Receivables can be defined as the total amount of collectibles for a company

Related Stocks
Company Name	Market Cap
Amgen (AMGN)	$171.5B
Vertex Pharmaceuticals (VRTX)	$119.5B
Regeneron Pharmaceuticals (REGN)	$114.6B
Gilead Sciences (GILD)	$103.4B
Bristol Myers Squibb (BMY)	$101.6B
CSL (CSLLY)	$97.4B
GSK (GSK)	$84.8B
Alnylam Pharmaceuticals (ALNY)	$35.2B
Argenex SE (ARGX)	$31.4B
Biogen (BIIB)	$28.2B
BioNTech SE (BNTX)	$28B
Moderna (MRNA)	$24.6B
Illumina (ILMN)	$21.1B
BeiGene (BGNE)	$20.7B
Genmab (GMAB)	$16B
BioMarin Pharmaceutical (BMRN)	$13.3B
Exact Sciences (EXAS)	$12.6B
Incyte (INCY)	$12.5B
Insmed (INSM)	$12.5B
Vaxcyte (PCVX)	$12.4B
Bio-Techne Corp (TECH)	$12.4B
Sarepta Therapeutics (SRPT)	$11.9B
QIAGEN (QGEN)	$10.3B
Bio-Rad Laboratories (BIO.B)	$9.1B
Ascendis Pharma (ASND)	$8.6B
Roivant Sciences (ROIV)	$8.6B
Legend Biotech (LEGN)	$8.5B
Repligen (RGEN)	$8.2B
Intra-Cellular Therapies (ITCI)	$7.7B
Exelixis (EXEL)	$7.5B